The Wegovy app explained: what it does, what it doesn't, and where a clinic fits in

You've heard about the Wegovy app and want to know if it's the thing that gets you started

Picture this: you've done your research, you know semaglutide exists, and someone's mentioned an app. Maybe you hoped it was a quicker route in, a sign-up form that bypasses a waiting room. It isn't, and it's worth understanding why before you spend time on it.

The app Novo Nordisk promotes alongside Wegovy in several markets is called WeGoTogether. It's designed as a companion for people who are already prescribed the injection, a place to log how they're feeling, set reminders for their weekly injection, and access educational content about eating habits and activity. Think of it as the support layer that sits around a clinical decision that's already been made.

What it cannot do is assess whether Wegovy is right for you. That requires a prescriber to look at your medical history, current medicines, weight, and BMI, and in the UK, to issue a valid NHS or private prescription. The regulatory pathway for Wegovy in the UK runs through the MHRA and NICE, not through a mobile app. Starting treatment before that assessment happens isn't a shortcut; it's just not possible through legitimate channels.

If you're at the beginning of the process, the right first step is a consultation, not a download.

What the WeGoTogether app includes for people already on Wegovy

For patients who are already prescribed and using Wegovy, a companion app does have genuine value. The weekly injection schedule (beginning at 0.25mg and titrating upward over several months toward 2.4mg, or now the newly approved 7.2mg for some patients) asks quite a lot of someone's memory and routine. A reminder system helps.

Beyond reminders, the app typically includes mood and wellbeing check-ins, prompts around hydration and protein intake (both practically important when appetite falls sharply on GLP-1 treatment), and content explaining what to expect at each dose stage. Some versions include a community element, connecting people in similar stages of treatment. You can find out more about what the Wegovy weight loss app offers and how it fits around treatment on the dedicated page.

Availability and features vary by region, and the UK version may differ from what's described in international coverage. The NHS patient information for semaglutide is the authoritative source for what's recommended around managing your treatment in the UK, and it will always point back to your prescriber for anything clinical.

One thing the app doesn't change: if a side effect concerns you, or you're not sure whether to move to the next dose, your prescriber is the right call. App content is general guidance, not a clinical opinion about your situation specifically.

How treatment actually starts in the UK, the practical picture

Since this page is often found by people who haven't yet started treatment, it's worth being concrete about how the process works through a regulated private service like nume.

You complete a free consultation online, medical history, current medicines, weight, what you've tried before. A GPhC-registered prescriber reads your answers the same day; a real clinician, not an automated filter. If treatment is clinically appropriate, a prescription is issued and your order is dispatched. Order before noon on a weekday and, once approved, it goes out the same day via DPD. It arrives the next working day, tracked to your door, in plain packaging with no branding on the outside. Inside is your Wegovy pen, cold-packed, ready to refrigerate when you get home.

If you're curious about how the injection is administered, the step-by-step guide to applying Wegovy covers that in practical detail. And for context on who the medicine is licensed for, the background on Wegovy's UK approval explains the eligibility picture clearly.

For anyone weighing up private costs before getting started, the weight-loss treatments page sets out what's included in a single transparent price, consultation, prescription, delivery and aftercare, no subscription.

Oral semaglutide: does an app help more when there's no injection involved?

In June 2026, the MHRA approved the first oral GLP-1 medicine for weight management in the UK, Wegovy in tablet form, reaching a 25mg daily maintenance dose. No injection, no cold chain, no need to refrigerate. It's a meaningful shift for people who found the idea of a weekly pen off-putting.

Whether a companion app is more or less useful for tablet-takers is a fair question. The daily timing requirement for the tablet is stricter than the weekly injection in one respect: it must be taken first thing in the morning on an empty stomach, with a small amount of plain water, and you should wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. An app reminder for that is arguably more practically valuable than a weekly injection nudge.

The clinical assessment requirement doesn't change with the format. Whether you're considering the injection or the tablet, the process starts with a prescriber. You can read more about semaglutide as a medicine (both forms) on the semaglutide overview page. If you're ready to find out whether Wegovy is suitable for you, start your free consultation and a prescriber will review your case the same day.